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Even the most effective drug product may be used improperly and thus ultimately prove
ineffective if it does not meet the perceptual, motor and cognitive capacities of its target
users. Currently, no comprehensive guideline for systematically designing user-centric
drug products that would help prevent such limitations exists. We have compiled a list of
approximate but nonetheless useful strategies—heuristics—for implementing a user-
centric design of drug products and drug product portfolios. First, we present a general
heuristic for user-centric design based on the framework of Human Factors and Ergo-
nomics (HF/E). Then we demonstrate how to implement this general heuristic for older
drug users (i.e., patients and caregivers aged 65 years and older) and with respect to three
specific challenges (use-cases) of medication management: (A) knowing what drug prod-
uct to take/administer, (B) knowing how and when to take/administer it, and (C) actually
taking/administering it. The presented heuristics can be applied prospectively to include
existing knowledge about user-centric design at every step during drug discovery, phar-
maceutical drug development, and pre-clinical and clinical trials. After a product has been
released to the market, the heuristics may guide a retrospective analysis of medication
errors and barriers to product usage as a basis for iteratively optimizing both the drug
product and its portfolio over their life cycle.
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1 | INTRODUCTION
The role of drug users—patients, caregivers and healthcare
professionals—in determining the effectiveness of drug products must
not be underestimated. If the design and accompanying informational
materials of drug products do not match users' needs and capacities,
the proper use—hence safety and effectiveness—of even the most
efficacious product can be compromised. In other words, drug prod-
ucts that are difficult to take/administer may not be used properly,
resulting in unnecessary medication errors, or may not be used at all,
jeopardizing therapeutic success.1-3
Patient-centric and, more generally, user-centric drug develop-
ment have recently gained attention in the pharmaceutical litera-
ture,4-6 the pharmaceutical industry,7 and the regulatory framework8
as a way to address this problem. Although the term “patient-centric”
is frequently used in the literature on drug development, we use
“user-centric” throughout this article to indicate that design efforts
should not be limited to patients alone but instead encompass all drug
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users, including patients, lay caregivers, pharmacists, nurses, physi-
cians, etc. The ultimate goal of user-centric drug development is to
support all drug users in taking and/or administering the right product
at the right dose, at the right moment, and in the right way in order to
reduce medication errors, especially in vulnerable populations such as
older adults9 and children.10 The only complete and coherent guide-
line that is at present available to help implement user-centric drug
development relates specifically to the development of drug products
for children.11 Another guidance document summarizes methods for
designing user-centric medical devices but does not address the spe-
cific challenges of user-centric drug product design.12 Our goal in this
paper is to provide approximate but useful strategies—heuristics—for
implementing a general user-centred drug design that can be adapted
and applied to different user groups and age groups.
To derive heuristic strategies for user-centric drug design, we con-
sulted with clinicians about common challenges for drug users and
searched for user-centric solutions in existing regulatory documents and
pharmaceutical guidelines and in the research base of Human Factors
and Ergonomics (HF/E). HF/E emerged as a field at the intersection
between psychology, engineering and economics at the outset of the
industrial revolution, when human error started to limit further produc-
tivity increases despite ongoing technological improvements.13 Workers
had to interact with increasingly sophisticated technology that taxed
their sensory, motor and cognitive capabilities—the human factors. The
impact of human factors on the effectiveness of human–machine sys-
tems was soon discovered in other fields, including the military, aviation
and medicine. In medicine, HF/E focuses mainly on the human factors
that emerge at the interface between professional users—physicians,
nurses, etc.—and medical devices/technologies in order to increase
patient safety and health system effectiveness,14,15 for instance via
barcode medication administration technology.16,17 In comparison, the
human factors of non-professional users of medical devices/technologies
(e.g., patients and lay caregivers) have gained little attention in HF/E
thus far,18 with the notable exception of users aged 65 and older.19
Based on our analysis, we first elaborate a general heuristic out-
lining how to structure user-centric design processes and focus on the
most essential steps. On the basis of this outline, we then present
more specific heuristics to address three specific tasks for drug
users—use-cases—involved in medication management:
Use-case A. Knowing what drug product to take/administer (i.e.,
identifying the correct product and being able to dis-
criminate among similar products);
Use-case B. Knowing how to take/administer the drug product (i.e.,
using a product at the right time, in the right way, and
for the right purpose);
Use-case C. Actually taking/administering the drug product (i.e.,
being able to handle a drug product, for instance by
opening drug containers/blisters, applying
inhalers/creams or administering multiple drugs)
To demonstrate how to implement the general heuristic with
respect to a particular user group, we describe the challenges for
patients and caregivers aged 65 and older within each use-case and
present available guidelines and/or evidence to outline heuristic
strategies for user-centric drug design. Older patients and care-
givers are the most vulnerable and at the same time the most com-
mon group of drug users.9 Thus designing drug products that this
group can use despite their specific perceptual, motor and cognitive
limitations (see Annex 1 in Ref.9) would more than likely prevent
the majority of medication errors, while reducing the severity of
those that do occur. The essence of the identified heuristics, which
may be applied to all drug users, including health professionals, is
summarized in Table 1. Because heuristics are approximate strate-
gies, we point out their limitations and how to address those limita-
tions at the end of the article.
2 | A GENERAL HEURISTIC FOR USER-
CENTRIC DESIGN
According to HF/E, the purpose of user-centric design is to support
smooth and error-free interactions between user and product so as to
meet task-specific goals (e.g., as implied in the use-cases above).12 To
serve this purpose, drug designers should follow three simple steps:
(1) identify relevant use-cases for a specific user group; (2) identify
the most serious challenges of these use-cases and any resulting com-
plications that must be avoided; and (3) identify design solutions that
support users best while minimizing the cognitive effort required to
use the product. We will first elaborate this three-step process and
then use it as a blueprint to derive more specific heuristics for the
user group of older patients and caregivers.
Step 1 in any user-centric design process is to define what a user
group should be able to do and achieve with a product. For this paper,
we identified three main tasks or use-cases that apply to all drug users
(see above). But of course, use-cases may vary from one user group to
another. For instance, medication reconciliation and creating a drug
formulary are use-cases specific to healthcare professionals. Thus
Step 1 is intended to define the use-case (e.g., actually taking a drug
product) and the goals and performance criteria for a specific user
group (e.g., older patients often take multiple drugs and thus must be
able to discriminate among similar products).
Step 2 is to define what should NOT happen when a product is
used. That is, in Step 2 drug designers should identify errors that could
occur when the requirements of a use-case cannot be met and rank
them according to the severity of the potential consequences. For
instance, which error might cause more harm for older patients: not
being able to grasp a tablet or not being able to swallow it? Depending
on the answer, the drug designer should prioritize solutions for errors
that have more severe consequences. The goal of Step 2, then, is both
to minimize harm for drug users and, at the same time, help drug
designers to prioritize in their planning of the design process.
Step 3 is to find user-centric solutions to the problems priori-
tized in Step 2, that is, solutions that help users to prevent errors
and minimize the cognitive effort needed for accurate task perfor-
mance. Such solutions will benefit all users but are essential if cog-
nitive, perceptual and/or motor skills are already limited (e.g., older
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patients and caregivers) or severely taxed (e.g., health professionals
working under stress).
According to HF/E, cognitive effort depends on the level of cogni-
tive control needed to perform a task.38,39 For instance, to minimize
the cognitive effort needed to differentiate between drug products,
instructions about how to recognize the visual differences between
them (a rule-based control task) should not be necessary. Instead, prod-
uct design should provide distinctive perceptual features (e.g., differ-
ences in size, colour or shape) so that users can directly “see”
differences between the drug products (making it a perceptual control
task). Similarly, to extract a product from its packaging (a motor control
task), no instructions should be required about where exactly to push
on a blister (a rule-based control task). Instead, physical properties (e.g.,
shapes, textures, and sizes) should be implemented that allow drug
users to “see” where to best open a blister (e.g., using convex rather
than concave/flat shapes). In HF/E, perceptual and physical features
that specify what users can or cannot do with a product are called
affordances.40 For product designers, they are an effective means of
making product functions apparent and thereby reducing cognitive
effort.41Of course, more complex tasks may require additional or even
all levels of cognitive control. For instance, to accurately
take/administer a drug product (Use-case B), users require simple
rules for how and when to take/administer it (rule-based control) plus
perceptual control and motor control to be able to implement these
rules. To manage complex diseases such as diabetes, drug users may
additionally require a conceptual model of how their disease works
and how to adapt medication management in order to control it (con-
ceptual control).39
As a general rule, perceptual control and motor control require
the least cognitive effort, followed by rule-based control and concep-
tual control.40,41 Thus in Step 3, designers should first try to find solu-
tions to support product usage (e.g., Use-cases A, B, C) at the
perceptual and motor levels before requiring users to engage in rule-
based or conceptual control.
TABLE 1 A set of heuristics for user-centric drug product designa
2. A general heuristic for user-centric design
Step 1: Define what should be done with a product (e.g., Use-case A, B or C).
Step 2: Define what should NOT be done with a product (e.g., prioritize potential medication errors).
Step 3: Identify what level of cognitive control is needed for the use-cases (i.e., perceptual, motor, rule-based or conceptual control) and minimize
related cognitive effort. In order to do so, user-centric design should support perceptual and/or motor control before requiring rule-based or
conceptual control.20,21
3.1 A specific heuristic for Use-case A: “Knowing what drug product to take/administer”
To support discrimination between products, use unique and consistent combinations of verbal labels and perceptual codes (e.g., colour, shape, size,
surface texture).
Continuous differences between products (e.g., concentration levels) should be coded using continuous perceptual dimensions (e.g., size, colour
saturation), whereas categorical differences between products (e.g., different ingredients) are best specified with categorically distinct perceptual
features (e.g., colour hues).22
Given that no guideline exists, perceptual codes must be iteratively usability tested.
3.2 Specific heuristics for Use-case B: “Knowing how to take/administer a drug product”
3.2.1 Use-case B1: Being able to read instructions23–26
To enhance readability, use a single sans-serif font at least 12 points in size. Also use line spacing of at least 1.5, with additional spacing between
paragraphs to separate distinct units of text. Lines should be no longer than 80 characters and left-justified without end-of-line hyphenation. Text
should be printed with high contrast.
3.2.2 Use-case B2: Being able to comprehend text
To design easy-to-comprehend text, information on why one should use the drug (purpose) should be provided first, then how much and how often it should
be used, and finally, its potential side effects.27 Comprehensibility is further enhanced by short and simple wording, active and positive sentences, argument
overlap, a non-alarmist tone, and a 4th- to 5th-grade reading level. Formatting and layout should underline the logical structure of the text.28
3.2.3 Use-case B3: Being able to comprehend numbers
To communicate numerical information, provide absolute numbers for risks and benefits with a comparison of two identical reference groups—usually
100 or 1000 people in both the intervention and control group.29,30 Fact boxes and icon-arrays are best practice for communicating numerical
information.31-33
3.2.4 Use-case B4: Being able to comprehend illustrations/diagrams
Illustrations/diagrams may increase comprehensibility. Given that people may differ in reading and graph literacy, illustrations/diagrams must be
accompanied by and closely aligned with explanatory text to maximize comprehensibility.28,34-36
3.3 A specific heuristic for Use-case C: “Actually taking/administering a drug product”
Facilitating motor control is key to preventing medication errors in the majority of users. Almond-shaped tablets,37 blisters with clearly specified
pushmarks, and tablets with clearly specified breakmarks are a good starting point.
To avoid confusing users, a perceptual feature should be used consistently and should support only one motor function. Potential trade-offs between
product handling and swallowability (e.g., related to size) should be considered.
Given that no guideline exists, design for motor control must be iteratively usability tested.
aHeuristics are defined as approximate but useful problem-solving strategies.
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The three-step process just outlined is summarized as a general
heuristic for user-centric design inTable 1. Of course, each step of this
general heuristic can and should be further specified depending on
the specific use-cases and the particular capacities and limitations of a
targeted user group. In what follows, we will show how this can be
done with the use-cases identified above and given the sensory,
motor and cognitive capacities of older patients and caregivers (see
Annex 1 in Ref.9). Based on this analysis and for each use-case, we will
provide more specific heuristics for user-centric drug product design.
The essence of these heuristics, which may be applied to all drug
users, is summarized inTable 1.
3 | SPECIFIC HEURISTICS FOR DESIGNING
USER-CENTRIC DRUG PRODUCTS
With the general heuristic in mind, we further specify the use-cases
identified above (Step 1) and outline potential sources of medication
errors (Step 2), using the example of older patients and caregivers.
Then we present available guidelines and evidence to help design drug
products that reduce cognitive effort for older patients and caregivers
(Step 3) and identify specific heuristics for user-centric drug design
and each use-case (Table 1).
3.1 | Use-case A: Knowing what drug product to
take/administer
In order for drug users to avoid medication errors, the first challenge
is to identify the correct product to use. This is a particularly
relevant task for older patients and caregivers who often use multi-
ple drug products (poly-pharmacy) that, to avoid harm, must not be
confused. In clinical practice, discriminability must be supported in at
least three types of scenarios. First, products may look alike but con-
tain categorically different ingredients (e.g., round white tablets).
Second, they may contain the same ingredient but at different levels
of strength or different concentrations. Third, innovator, generic and
parallel-imported products may essentially provide the same ingredi-
ent at the same strength or concentration but may look entirely dif-
ferent. Psychologists suggest that our ability to discriminate between
objects depends on the availability and reliability of easy-to-
recognize differentiating features.42,43 To design drug products that
help users to identify the correct product to take/administer in the
above-mentioned clinical practice scenarios, two categories of
product-discriminating features may be used: conceptual distinctions
(names or verbal labels) and perceptual features (colour, shape, size,
surface texture or combinations thereof).
With respect to product naming/labelling, guidelines focus mainly
on text formatting (e.g., font, font size, margins) to increase readabil-
ity rather than discriminability.23,24 To help discriminate between
similar names for different drug products, the US Food and Drug
Administration (FDA)44 and the European Medicines Agency (EMA)8
recommend Tall Man Lettering. That is, letters that help differentiate
between similar medication names should be capitalized (e.g.,
DOBUTamine versus DOPamine). But even if Tall Man Lettering is
applied, verbal labels require both a certain level of visual acuity (see
Figure 1, example 1) and cognitive resources for the decoding and
processing of the verbal information. Both are common challenges
for older patients and caregivers9 and sometimes also for health
F IGURE 1 Examples of the front side (left) and back side (right) of four drug products (one per row), each with different and more or less
effective codes to specify differences in strength. From top to bottom, the following examples are shown:
1. Lisinopril 5, 10, 20 mg (strength is coded verbally, but readability may be low due to small font size, especially if visual acuity is low).
2. Enalapril 5, 10, 20 mg (strength is coded with shape and colour; switch of codes between 5 mg and 10/20 mg may obscure the fact that the
tablets contain the same ingredient).
3. Olanzapin velotab 5, 10, 15, 20 mg (strength is coded using proportional changes in size to support comparisons; information on absolute
strength cannot be inferred without additional verbal labels).
4. Diazepam 2, 5, 10 mg (strength is coded verbally and with colour; colour codes for continuous variables such as strength must be learned and
remembered, potentially taxing users' cognitive resources; however, colour may be effective for specifying categorical differences, e.g.,
between ingredients)
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professionals who have to work in busy and stressful environments.
To solve these problems, perceptual features may be used to help
drug users directly “see” differences between products as well as
their immediate and secondary packaging. We review examples of
how this can be done using both the literature and clinical practice
in turn.
In the literature, very few official standards for how to specify
differences between drug products at the perceptual level have been
identified. For instance, there is an ISO standard for colour codes to
differentiate syringe types (ISO 26825)45 and an American Academy
of Ophthalmology (AAO) colour code for caps and labels to help dif-
ferentiate between topical ocular drugs.46 Nevertheless, although
colour codes are often used in marketing to communicate brand
and/or product identity, there is no official colour code in use to
specify categories of ingredients or levels of strengths or concentra-
tions of drug products. Empirically, however, there is promising yet
insufficient evidence on how perceptual features may be used to
specify product differences.47,48 Initial evidence from the laboratory
suggests that patients and caregivers tend to use bottle colour,
shape and size more frequently and, in the case of colour, more cor-
rectly than product names to differentiate between medications.49
But the same study also showed that colours alone are insufficient
to support unambiguous patient–doctor communication about drug
products.50 Thus the ability to differentiate between medications
should be supported with a complementary combination of percep-
tual and verbal codes.
From a clinical perspective, most ointments are provided in simi-
larly shaped tubes and, apart from a few drug products with consistent
colour codes (e.g., red/pink for ibuprofen, light blue for sildenafil),
most tablets are white, round and packed in similar-looking boxes and
bottles. In Figure 1, we compare four examples of how perceptual
(and verbal) features are currently used to code differences in the
strength of the same ingredient, and then we illustrate potential
pitfalls. The examples underline an HF/E principle stating that
user-centric design should align perceptual codes with task character-
istics.22 Specifically, to differentiate continuous differences between
drug products (e.g., strength, dose or concentration of the same ingre-
dient), a continuous perceptual dimension (e.g., size, colour saturation)
should be used (e.g., Figure 1, example 3). Categorical differences
between drug products (e.g., different ingredients) are best specified
using categorically different perceptual features (e.g., distinct colour
hues). Figure 2 provides an example where this principle is not
followed and further suggests that, for optimal support, differences
between drug products must be easy to recognize across all contexts
of use, for instance while the product is still packaged and once it has
been removed from its packaging.
There are also scenarios when using perceptual features to aid
in discrimination is problematic. For instance, discrimination based
on colour and shape may be compromised if the same features
already serve other functions like corporate identity or brand iden-
tity. Also, the options for perceptual coding may be limited by drug
user characteristics (e.g., red-green colour blindness) and by cultural
conventions. One example of such a convention is that, compared to
black-and-white stimuli, red and orange colours tend to be associ-
ated with warnings or danger in most cultures51,52 and have a
stimulant effect compared to more tranquillizing blue and green col-
ours.53 The essence of this heuristic is summarized in Table 1
(Specific heuristic for Use-case A: “Knowing what drug product to
take/administer”).
3.2 | Use-case B: Knowing how to take/administer a
drug product
A second challenge for drug users is to understand which product
should be taken when, how and for what purpose. Drug users also
need to know what side effects may occur, how to recognize them,
and what to do if they occur. Examples from clinical practice sug-
gest that putting this information into action is quite challenging, in
particular for older drug users. Older patients and their caregivers
often need to fit multiple drugs into a treatment plan (poly-phar-
macy), each with specific but different instructions related to dos-
ing, intake frequencies (e.g., weekly versus daily), etc.2,3 In addition,
if existing drug formulations do not match individual needs, drug
users may have to combine several strengths, subdivide, or other-
wise modify products prior to use. Without adequate understand-
ing of a product's characteristics, even healthcare professionals may
incorrectly crush tablets or open capsules, potentially altering
absorption characteristics and putting their patients and themselves
at risk.54
If correct drug administration is not well explained and
supported, patients may end up taking incorrect doses of drugs at
incorrect frequencies, swallowing blisters rather than the tablet
itself, taking suppositories orally, or spraying inhalers into the air
rather than into their mouths. In combination with potential
declines of cognitive functioning, medication management/adminis-
tration becomes a major challenge for older patients and their care-
givers. To help this user group manage medication regimens and
avoid errors or, worse, non-adherence, information about how to
correctly use a drug product must be particularly easy to
F IGURE 2 The packaging of Olanzapin velotab (Zyprexa) 5, 10,
15 and 20 mg strengths are shown here from left to right. The
differences in strength (a continuous variable) are colour coded on the
upper part of the packaging using different hues, suggesting
categorical differences between the tablets. Once the packaging is
removed, all tablets are off-white and differ only marginally in size
between 5 and 10 mg and 15 and 20 mg, hampering recognition of
differences in strength
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comprehend.2,3,9,55 In our own research we have in fact shown for
a cancer self-screening context that, if health information is tailored
to the needs of older patients, errors can be reduced56 and adher-
ence increased.57
Knowing how to accurately take/administer drug products mainly
requires rule-based control and conceptual control, both of which
may be best supported with (written) instructions and medication lists
summarizing which product to take, when and at what dose.38,39 As
an alternative to written instructions, videos have also been used suc-
cessfully (e.g., Vision Leaflets, which can be accessed at https://www.
kijksluiter.nl/, are available for patients and caregivers in a number of
different languages and adjusted to different cultural backgrounds).
But given that written text is the most common format for communi-
cating medication instructions, we will focus on designing user-centric
written instructions here. Instructional information for healthcare pro-
fessionals is provided in the Summary of Product Characteristics
(SmPC), which can be retrieved from regulatory databases. For
patients, this information is provided in package leaflets or on the
package label. Based on the available literature and existing guidelines,
we can elaborate specific solutions for several scenarios that can
occur within the construct of Use-case B: users must be able to read
instructions, even if visual acuity is reduced (Use-case B1); and users
must comprehend instructional text (Use-case B2), numbers commu-
nicating risks and benefits (Use-case B3), and illustrations/diagrams
(Use-case B4), even if they are novice healthcare professionals, under
stress, anxious or have low health literacy levels. We elaborate on
these scenarios in the following and summarize the heuristics for Use-
case B inTable 1.
3.2.1 | Use-case B1: Being able to read instructions
Several guidelines exist for writing instructional text on how to use
drug products,23-26 although they may not always be closely
followed.58 Here we present the most important principles. To
improve readability of instructions and support (older) drug users with
limited visual acuity, contrast should be high (at least 5:1) with black
font on white paper. No more than two types of sans-serif fonts (e.g.,
Arial or any other font without small extensions called “serifs” at the
ends of its characters) should be used (for easy-to-read fonts, see DIN
1450:2013-04), and print should be at least 12 points in size. Headers
should be clearly and consistently marked. Lines should be no longer
than 80 characters (4.7 inches or 12 cm) and should be left-justified
without end-of-line hyphenation. Line spacing should be set at 1.5
with more than 1.5 lines left between paragraphs to help readers sep-
arate distinct units.
3.2.2 | Use-case B2: Being able to comprehend
instructional text
Instructional text may be made more comprehensible by presenting
drug information in a preferred order. Older adults prefer general
information about the drug (purpose) to be first, then information
about how to take the product (dose and schedule), and finally infor-
mation about possible side effects.27 The literature suggests that com-
prehensibility may be enhanced with simple rather than technical
wording, a short-and-clear rather than complex sentence structure,
active rather than passive formulations, positively framed sentences
rather than negatively framed ones, and a descriptive text at a 4th- to
5th-grade reading level.59 Sentences must be consistent and should
provide sufficient argument overlap to avoid misinterpretations.59 To
help readers visually connect related contents in a written text,
section headings, list formats,60 flow charts and boxes are effective.
Key words can be made bold to facilitate retrieval. To mark a change
in content, text structure or topic, new paragraphs and extra spacing
are effective.61,62 Finally, recent guidelines suggest that, to support
patient participation, instructional language should be non-alarmist
and non-patronizing.26
3.2.3 | Use-case B3: Being able to comprehend
numbers
Communication of numerical information is hampered mainly by
limited numeracy skills63 and ambiguous numerical formats such as
relative risks (e.g., a medication decreases the probability of a
stroke by 48%) that cannot be interpreted without base rates of
the risk.29 To circumvent these problems, risks and benefits of a
drug product are best communicated in absolute numbers and as a
comparison of two identical reference groups of patients, one
which uses and one which does not use the product for a specified
period of time (e.g., the probability of a stroke decreases from 28
out of 1,000 men not taking the medication to 15 out of 1,000
men taking the medication over a period of 10 years).29,30 Ideally,
this information is provided in what is known as drug factboxes.31
Factboxes are 2×2 tables summarizing evidence for risks and bene-
fits in intervention and control groups, that is, for those who used
and those who did not use the drug product (for a guideline on
how to create factboxes, see Ref.64).
Those with low numeracy skills may benefit from visually repre-
sented numbers,26 with a symbol (icon) repeated a specific number of
times, the repetition typically representing 100 or 1,000 people. An
example is provided in Figure 3, where icon arrays visually compare
the benefits of an imaginary drug product for 1,000 people taking it as
compared to 1,000 people not taking it for a specified period of time.
The number of those who are expected to be at risk for a stroke in
each population is marked in colour. Such visuals may be provided on
Summary of Product Characteristics (SmPC) and package leaflets.
They may also be used by healthcare providers in clinical settings in
order to transparently communicate the benefits and risks of a drug
product to potential users. Numerous studies have demonstrated that
icon arrays are an effective tool for communicating health risks,33,65
enhancing knowledge and reducing common biases (e.g., framing,
denominator neglect, anecdotal reasoning), particularly for users with
lower numeracy skills.33,65,66
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3.2.4 | Use-case B4: Being able to comprehend
illustrations
Finally, illustrations/diagrams may increase attention to and recall of
drug product instructions,34 in particular if clearly linked to written or
spoken text.35 Although illustrations/diagrams tend to reduce the
need for orthographic decoding, especially for older adults,28,36 recent
research shows that individual differences related to both reading and
graph literacy do matter. Populations with low reading literacy seem
to benefit from illustrations/diagrams, but only if they are combined
with a short oral or written explanation of the visual elements and the
messages that they are intended to convey.35 To communicate the
numerical risks and benefits of drug products, illustrations/diagrams
tend to increase comprehension and recall in people with high graph
literacy.67 However, people with low graph literacy tend to be better
informed when information is given in numbers. Thus, to maximize
benefits, both formats should be provided.
3.3 | Use-case C: Actually taking/administering a
drug product
A third important challenge for drug users relates to the handling of a
product and its package. Product and package handling are mainly
perceptual and motor tasks that should require little rule-based or
conceptual control. However, drug users, especially older patients and
caregivers, may have limited perceptual and/or motor functions, such
as problems with grasping and unsteady hands (dexterity)68,69 or
problems swallowing (dysphagia).9 If product or package design fails
to compensate for limited perceptual and/or motor skills, drug users
may invent work-arounds. In other words, if motor control is
F IGURE 3 Examples of icon-arrays communicating the baseline risk of a stroke for a defined population of 1,000 people without drug
product (left) compared to 1,000 people taking an imaginary drug product aimed at reducing this risk (right). Potential side effects are omitted in
this example but may also be included using another colour. Icon-arrays were generated using http://www.iconarray.com
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hampered, drug users may need to engage in rule-based and/or con-
ceptual control, taxing their cognitive capacities and increasing the
probability of medication errors. For instance, if blisters cannot be
readily opened, tablets may end up being crushed, or a user may
extract all of the tablets at once and transfer them to a container,
increasing the risk of unintended under or overmedication.68 Similarly,
if capsules cannot be easily swallowed, a user/administrator may open
them, potentially altering drug absorption (e.g., enteric-coated medica-
tions).70 In older patients, both problems may be exacerbated due to
poly-pharmacy.
Based on our knowledge, no guideline exists for designing
easy-to-open packaging or easy-to-swallow drug products for a
defined user population, except for the development of drug prod-
ucts for children.11 Until more guidelines become available, the
perceptual and motor requirements of the most common and vul-
nerable population—older patients and their caregivers—should be
taken into consideration in order to maximize the potential benefit
for this user group (and most probably for the majority of other
user groups as well).
To facilitate a user's motor control of drug products, perceptual
features that specify where to push on a blister (convex rather than
concave/flat shapes) or where and how to break a tablet (breakmarks)
should be used. Importantly, each perceptual feature should be used
to specify and support one function only. That is, features that look
like breakmarks but are meant to support swallowing rather than
accurate dosing may mislead drug users, including health profes-
sionals, and must be avoided. With respect to package handling, some
mechanisms for extracting tablets from a blister may require lower
levels of dexterity (e.g., push-through versus peel-off blisters) or less
opening force (e.g., plastic versus aluminium foil). Even push-through
blisters may be an obstacle for users with limited dexterity, however,
so that other solutions, such as easy-to-open medication boxes, may
be a better choice. On the other hand, such boxes need to be child-
proof (i.e., not too easy to open) to avoid the risk of accidental poison-
ing in children. These examples illustrate that, ultimately, what
constitutes an easy and safe-to-handle drug product is highly depen-
dent on the context of use. Thus to develop user-centric products,
any design must be iteratively usability tested and improved with the
involvement of the targeted drug users in their respective contexts of
use.68,69,71 In this process, designers should also consider that percep-
tual features may involve trade-offs (e.g., larger tablets may facilitate
grasping but hamper swallowing).
To support swallowability, drug product designers need to con-
sider perceptual and motor features related to tablet shape,
size/diameter, surface texture and taste/smell,72 but of course
within the boundaries set by pharmacology (e.g., absorption path-
ways, dosing). First evidence suggests that size/diameter of tablets
seems to be less relevant than shape. A recent study shows that, in
a population without problems swallowing, almond-shaped tablets
are easiest to swallow compared to elongated and round tablets,
even though the almond-shaped tablet is wider than the latter
two.37 Where absorption pathways allow, other routes of adminis-
tration may be considered. For instance, patients with dysphagia
tend to prefer dispersible/effervescent or orally disintegrating tab-
lets over chewable tablets and granules.73 Also, ointments,
powder,70 liquids or injections74 may help to facilitate product han-
dling for certain user groups and in certain contexts of use. If the
medication must be in tablet form, package leaflets should specify
whether the drug may be co-administered or mixed with food or
drink to ease swallowing and, if so, provide simple rules as to how
this should be done to avoid medication errors. Again, the route of
administration that best supports target users in their various con-
texts of use must be identified based on the results of iterative
usability testing. For a summary, see the specific heuristic for Use-
case C in Table 1.
4 | LIMITATIONS OF HEURISTICS AND
HOW TO ADDRESS THEM
Heuristics are approximate problem-solving strategies. One advantage
of such strategies is that they are somewhat generic and thus flexible
enough to be applied to different user groups and used across various
contexts and by various stakeholders. For instance, the presented
heuristics can be used by drug designers, but may also be used by
health professionals in clinical practice settings to anticipate and over-
come obstacles related to correct drug product use (e.g., to explain to
patients how to split tablets in order to prevent their having problems
swallowing them, or how to use different pill containers for products
that contain different substances but look alike, or to clarify that, in
the case of generic substitution, a product may contain the same sub-
stance even though it is from a different company). The main disad-
vantage of heuristics, on the other hand, is that they do not provide
foolproof solutions for all possible scenarios of drug product design. In
the following, we elaborate on some of the limitations of the pres-
ented heuristics and on helpful methods for addressing those
limitations.
First, what constitutes a user-centric solution for one use-case
may not be user-centric for another. For instance, shapes that are
easy to discriminate one from another (Use-case A) may not be
easy to swallow (Use-case C), and easy-to-comprehend instructions
(Use-case B) may be ineffective if the product cannot be easily
unpacked (Use-case C). Because trade-offs between different use-
cases cannot be reliably predicted, iterative prototyping and usabil-
ity testing before and during the drug development process—in
both laboratory and real-world/clinical contexts of use—are
essential.75
Second, we focused mainly on older patients and caregivers as
the most common and vulnerable drug users. Other user groups may
have different requirements with respect to the presented use-cases
(e.g., children). And other use-cases may exist, for instance, for
healthcare professionals, such as medication reconciliation or compil-
ing a drug formulary. Thus, for user-centric design, all potential users
of a drug product—patients, caregivers, physicians, pharmacists and
other healthcare professionals—should be considered, specifically
their particular perceptual, motor and cognitive capacities and
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limitations and the unique tasks and problems they might face in dif-
ferent contexts of use.28
Third, whether a drug product is user-centric depends not only
on the match between a product and user characteristics, but also
on how users understand, perceive and take/administer the product
in their specific context of use (e.g., at home vs. in the hospital, with
vs. without caregivers, with innovator vs. generic products). In other
words, sources of medication errors related to misunderstandings
and false impressions of drug products can be anticipated only to
some degree and will be fully revealed only in practice. To avoid
unanticipated problems at the stage of implementation, designers of
user-centric drug products should learn to “walk in the shoes” of the
user by applying, for instance, ethnographic in situ observations
before and during the early phases of drug development.76 These
methods provide valid information about use scenarios (i.e., the situa-
tions in which drug products need to be taken) and about how drug
users understand, experience and take/administer a drug product in
their actual contexts of use. As a result, possible misunderstandings,
false impressions, and misuses of drug products may be revealed to
inform (re-)designs and to help avoid similar misconceptions in the
future.
Finally, because clinical practice changes over time, user-centric
drug product design is an ongoing challenge. To meet this challenge,
pharmaceutical companies and drug developers should focus on a
user-centric development of new drug products (prospective
approach) and re-evaluate patterns of use and medication errors for
products already or about to be released to the market (retrospective
approach). A combination of methods for prospective and retrospec-
tive analyses is best suited to guarantee that drug products and
related portfolios meet user requirements for safe and effective drug
product use and remain state of the art over their entire life cycle.
For both the prospective and the retrospective approach, HF/E
provides a substantial inventory of methods. We give abbreviated
descriptions of the most important methods here but recommend a
look at the comprehensive list provided in Ref.12 To identify user
requirements prospectively, the most widely used methods are
observations, interviews and surveys. Whereas observations (also
called contextual inquiry) are best used to yield information about
use scenarios (see above), interviews—performed individually or in
focus groups—are best suited to define user types (often called per-
sonas) with their distinctive goals, desires, capacities and limitations.
To identify use-cases (i.e., what users need to do and what they
should not do), health professionals should be interviewed. Surveys
are the method of choice for quantifying the observed differences
between user types and use cases in larger and more representative
samples.
For retrospective product evaluations before and after release to
the market, methods can be classified as analytical versus empirical
and task-based versus rule-based. Whereas analytical methods rely
mainly on experts of user-centric design (e.g., HF/E professionals,
physicians, pharmacists) for product evaluations, empirical methods
analyse interactions between actual users and the product/prototype.
For instance, in cognitive walkthroughs, a well-known analytical, task-
based method, experts are asked to “think aloud” while performing a
given task (e.g., the use-cases) with the product. For heuristic
evaluations,77 a widely used analytical, rule-based method, experts are
asked to evaluate a product based on design heuristics (e.g., the spe-
cific heuristics for Use-case B in Table 1). Empirical methods are gen-
erally task-based and often referred to as usability tests. Here, non-
professional drugs users (e.g., patients, caregivers) and professional
drug users (e.g., physicians, nurses, pharmacists) may be asked to
“think aloud” while using a product or interviewed and/or requested
to fill out standardized usability surveys after product use. Once a
product has been released to the market, ongoing usability testing, in
situ observations and analyses of case reports (e.g., using
pharmacovigilance systems) may provide the best sources for specify-
ing user-centred redesigns and related improvements of drug prod-
ucts and portfolios.
5 | CONCLUSIONS
From an HF/E perspective, even the most effective drug product will
not be used properly—or at all—and will therefore ultimately be inef-
fective if it does not meet the perceptual, motor and cognitive capaci-
ties (including health literacy) of the target user population. To date,
there is no one recipe, let alone a complete and coherent guideline,
for how to implement user-centric drug design for different user
populations and across the product life cycle. But based on lessons
learned from HF/E, the heuristics presented in this article will help
drug designers to take important first steps towards introducing
and/or strengthening a user-centric perspective in the drug develop-
ment process, as well as assist health professionals in clinical practice
in anticipating, identifying and hopefully overcoming major obstacles
to correct drug product use with their patients.
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